Transplant-Related Disorder
24
6
6
8
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.3%
2 terminated out of 24 trials
80.0%
-6.5% vs benchmark
21%
5 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (24)
Quantra® System With the QPlus® Cartridge in Double-lung Transplantation
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT
Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
A Cohort Study on the Association Between the ANS Function and Acute GvHD
Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Treatment Chronic UTI Post Kidney Transplant
Improving Frailty With a Rigorous Ambulation Intervention in Lung Transplant Patients
Optimal Timing of Hepatitis B Vaccination After Transplants
Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model
Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model
Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.
Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates
EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS
Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell Transplant
Neuropsychological and Biopsychosocial Evolution During Pediatric Transplantation: Pre/Post-stages and at 6 Months
N-acetyl Cysteine for the Prevention of Oral Mucositis After Autologous Hematopoietic Cell Transplantation.